Cost-Effectiveness Comparison Of Botulinum Toxin Type A Plus Best Supportive Care Versus Best Supportive Care Alone In The Treatment Of Idiopathic Overactive Bladder With Urinary Incontinence Among Patients Not Adequately Managed By Anticholinergic Therapy In France.

Ruffion, A; Velard, M; Loveman, C; Khalaf, K; Roze, S; Pignata, M; Stanisic, S; Lister, J

Ruffion, A; Velard, M; Loveman, C; Khalaf, K; Roze, S; Pignata, M; Stanisic, S; Lister, J.

Afiliação

Ruffion A; Centre Hospitalier Lyon Sud, Pierre Bénite, France.
Velard M; Allergan France SAS, Courbevoie, France.
Loveman C; Allergan Holdings Ltd., Marlow, UK.
Khalaf K; Allergan, Inc, Irvine, CA, USA.
Roze S; HEVA HEOR, Lyon, France.
Pignata M; HEVA HEOR, Lyon, France.
Stanisic S; The LASER Group, Milano, Italy.
Lister J; Laser Analytica, Loerrach, Germany.

Value Health ; 17(7): A470, 2014 Nov.

Article em En | MEDLINE | ID: mdl-27201348

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Value Health Assunto da revista: FARMACOLOGIA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google